Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Приверженность к терапии больных с болезнью Паркинсона и пути ее повышения
Приверженность к терапии больных с болезнью Паркинсона и пути ее повышения
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Безносюк Е.В., Соколова Е.Д. Механизмы психологической защиты. Журн. неврол. и психиатр. им. С.С.Корсакова 1997; 2: 44–8.
2. Данилов Д.С. Механизмы формирования комплайенса. Российские мед. вести. 2008; 13 (4).
3. Конради А.О. Значение приверженности к терапии в лечении кардиологических заболеваний. Справоч. поликлинич. врача. 2007; 4 (6).
4. Левин О.С, Федорова Н.В. Болезнь Паркинсона. М.: Медпресс-информ. 2011; с. 325.
5. Ammassari A, Trotta MP, Murri R et al. Self-reported sexual dysfunction is frequent among HIV-infected persons and is associated with suboptimal adherence to antiretrovirals. AIDS Patient Care STDS 2008; 22: 291–9.
6. Bull SA, Hunkeler EM, Lee JY et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother 2002; 36: 578–84.
7. Bull SA, Hu XH, Hunkeler EM et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA 2002; 288: 1403–9.
8. Chung TH, Deane KH, Ghazi-Noori S et al. Systematic review of antidepressant therapies in Parkinson's disease. Parkinsonism Re-lat Disord 2003; 10: 59–65.
9. Cramer J, Vachon L, Desforges C, Sussman NM. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia 1995; 36: 1111–7.
10. Colcher IS, Bass JW. Penicillin treatment of streptococcal pharyngitis. A comparison of schedules and the role of specific counseling. JAMA 1972; 222: 657–9.
11. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance Clin Ther 2001; 23: 1296–131.
12. Ekedahl A, Mansson N. Unclaimed prescriptions after automated prescription transmittals to pharmacies. Pharm World Sci 2004; 26: 26–31.
13. Foltynie T, Brayne CE, Robbins TW et al. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004; 127: 550–60.
14. Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson’s disease. Mov Disord 2005; 20 (11): 1502–7.
15. Grosset KA, Reid JL, Grosset DG. Medicine-taking beh * avior: implications of suboptimal compliance in Parkinsons disease. Mov Disord 2005; 20: 1397–404.
16. Grosset D, Antonini A, Canesi M et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord 2009; 24: 826–32.
17. Hamilton GA. Measuring adherence in a hypertension clinical trial. J Manag Care Pharm 9 (5): 424–9.
18. Higgins N, Regan C. A systematic review of the effectiveness of interventions to help older people adhere to medication regimes. Age Ageing 2004; 33 (3): 224–9.
19.Hill M, Houston N. Adherence to antihypertensive therapy. Chapter 131: 390–2.
20. Hobson P, Meara J. The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson's disease by use of the CAMCOG neuropsychological test. Age Ageing 1999; 28: 39–43.
21.Huffman MH. Compliance, health outcomes, and partnering in PPS: acknowledging the patient’s agenda. Home Healthcare Nurse 2005; 23 (1): 23–8.
22. Kulkarni AS, Balkrishnan R, Anderson RT et al. Medication adherence and associated outcomes in medicare health maintenance organization enrolled older adults with Parkinson’s disease. Mov Disord 2008; 23: 359–65.
23. McLaughlin EJ, Raehl CL, Treadway AK et al Assessing medication adherence in the elderly: which tools to use in clinical practice? Drugs Aging 2005; 22 (3): 231–55.
24. McDonald WM, Richard IH, DeLong MR. Prevalence, etiology and treatment of depression in Parkinson's disease. Biol Psychiatry 2003; 54: 363–75.
25. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of self-reported measure of medical adherence. Med Care 1986; 24: 67–73.
26. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002; 288: 2868–79.
27. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487–97.
28. Pahwa R, Factor SA, Lyons KE et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Neurology 2006; 66: 983–95.
29. Peterson AM, Takiya L, Finley R. Meta-analysis of trials of interventions to improve medication adherence. Am J Health Syst Pharm 2003; 60 (7): 657–65.
30. Rudd P, Ahmed S, Zachary V et al. Improved compliance measures: applications in an ambulatory hypertensive drug trial. Clin Pharmacol Ther 1990; 48: 676–85.
31. Ruscin JM, Semla TP. Assessment of medication managements kills in older outpatients. Ann Pharmaco Ther 1996; 30 (10): 1083–8.
32. Richter A, Anton SF, Koch P et al. The impact of reducing dose frequency on health outcomes. Clin Ther 2003; 25 (8): 2307–35.
33. Salzman C. Medication compliance in the elderly. J Clin Psychiatry 1995; 56: 18–22.
34. Schlenk EA, Dunbar-Jacob J, Engberg S. Medication non-ad-herence among older adults: a review of strategies and interventions for improvement. J Gerontol Nurs 2004; 30 (7): 33–43.
35. Schwab R, England AC Jr. Projection Techniques for Evaluating Surgery in Parkinsons Disease. Third Symposium on Parkinson's Disease, Royal College of Surgeons, 1968. Edinburgh: E&S Livingstone LTD, 1968; p. 152.
36. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods , validity, and applications.
J Clin Epidimiol 1997; 50: 105–16.
37. Strelec MA, Mion AM. The influence of patient’s consciousness regarding high blood pressure and patient’s attitude in face of disease controlling medicine intake. Arc Bras Cardiol 2003; 81: 349–54.
38. Stilley CS, Sereika S, Muldoon MF, Ryan CM, Dunbar-Jacob J. Psychological and cognitive function: predictors of adherence with cholesterol lowering treatment. Ann Behav Med 2004; 27: 117–24.
39. Stewart MA. Effective physician-patient communication and health outcomes: a review. CMAJ 1995; 152 (9): 1423–33.
40. Urquhart J. Role of patient compliance in clinical pharmacokinetics. A review of recent research. Clin Pharmacokinet 1994; 27: 202–15.
41. Waeber B. Treatment strategy to control blood pressure optimally in hypertensive patients. Blood pressure 2001; 10: 62–73.
2. Данилов Д.С. Механизмы формирования комплайенса. Российские мед. вести. 2008; 13 (4).
3. Конради А.О. Значение приверженности к терапии в лечении кардиологических заболеваний. Справоч. поликлинич. врача. 2007; 4 (6).
4. Левин О.С, Федорова Н.В. Болезнь Паркинсона. М.: Медпресс-информ. 2011; с. 325.
5. Ammassari A, Trotta MP, Murri R et al. Self-reported sexual dysfunction is frequent among HIV-infected persons and is associated with suboptimal adherence to antiretrovirals. AIDS Patient Care STDS 2008; 22: 291–9.
6. Bull SA, Hunkeler EM, Lee JY et al. Discontinuing or switching selective serotonin-reuptake inhibitors. Ann Pharmacother 2002; 36: 578–84.
7. Bull SA, Hu XH, Hunkeler EM et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA 2002; 288: 1403–9.
8. Chung TH, Deane KH, Ghazi-Noori S et al. Systematic review of antidepressant therapies in Parkinson's disease. Parkinsonism Re-lat Disord 2003; 10: 59–65.
9. Cramer J, Vachon L, Desforges C, Sussman NM. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia 1995; 36: 1111–7.
10. Colcher IS, Bass JW. Penicillin treatment of streptococcal pharyngitis. A comparison of schedules and the role of specific counseling. JAMA 1972; 222: 657–9.
11. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance Clin Ther 2001; 23: 1296–131.
12. Ekedahl A, Mansson N. Unclaimed prescriptions after automated prescription transmittals to pharmacies. Pharm World Sci 2004; 26: 26–31.
13. Foltynie T, Brayne CE, Robbins TW et al. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004; 127: 550–60.
14. Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson’s disease. Mov Disord 2005; 20 (11): 1502–7.
15. Grosset KA, Reid JL, Grosset DG. Medicine-taking beh * avior: implications of suboptimal compliance in Parkinsons disease. Mov Disord 2005; 20: 1397–404.
16. Grosset D, Antonini A, Canesi M et al. Adherence to antiparkinson medication in a multicenter European study. Mov Disord 2009; 24: 826–32.
17. Hamilton GA. Measuring adherence in a hypertension clinical trial. J Manag Care Pharm 9 (5): 424–9.
18. Higgins N, Regan C. A systematic review of the effectiveness of interventions to help older people adhere to medication regimes. Age Ageing 2004; 33 (3): 224–9.
19.Hill M, Houston N. Adherence to antihypertensive therapy. Chapter 131: 390–2.
20. Hobson P, Meara J. The detection of dementia and cognitive impairment in a community population of elderly people with Parkinson's disease by use of the CAMCOG neuropsychological test. Age Ageing 1999; 28: 39–43.
21.Huffman MH. Compliance, health outcomes, and partnering in PPS: acknowledging the patient’s agenda. Home Healthcare Nurse 2005; 23 (1): 23–8.
22. Kulkarni AS, Balkrishnan R, Anderson RT et al. Medication adherence and associated outcomes in medicare health maintenance organization enrolled older adults with Parkinson’s disease. Mov Disord 2008; 23: 359–65.
23. McLaughlin EJ, Raehl CL, Treadway AK et al Assessing medication adherence in the elderly: which tools to use in clinical practice? Drugs Aging 2005; 22 (3): 231–55.
24. McDonald WM, Richard IH, DeLong MR. Prevalence, etiology and treatment of depression in Parkinson's disease. Biol Psychiatry 2003; 54: 363–75.
25. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of self-reported measure of medical adherence. Med Care 1986; 24: 67–73.
26. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002; 288: 2868–79.
27. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005; 353: 487–97.
28. Pahwa R, Factor SA, Lyons KE et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review). Neurology 2006; 66: 983–95.
29. Peterson AM, Takiya L, Finley R. Meta-analysis of trials of interventions to improve medication adherence. Am J Health Syst Pharm 2003; 60 (7): 657–65.
30. Rudd P, Ahmed S, Zachary V et al. Improved compliance measures: applications in an ambulatory hypertensive drug trial. Clin Pharmacol Ther 1990; 48: 676–85.
31. Ruscin JM, Semla TP. Assessment of medication managements kills in older outpatients. Ann Pharmaco Ther 1996; 30 (10): 1083–8.
32. Richter A, Anton SF, Koch P et al. The impact of reducing dose frequency on health outcomes. Clin Ther 2003; 25 (8): 2307–35.
33. Salzman C. Medication compliance in the elderly. J Clin Psychiatry 1995; 56: 18–22.
34. Schlenk EA, Dunbar-Jacob J, Engberg S. Medication non-ad-herence among older adults: a review of strategies and interventions for improvement. J Gerontol Nurs 2004; 30 (7): 33–43.
35. Schwab R, England AC Jr. Projection Techniques for Evaluating Surgery in Parkinsons Disease. Third Symposium on Parkinson's Disease, Royal College of Surgeons, 1968. Edinburgh: E&S Livingstone LTD, 1968; p. 152.
36. Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods , validity, and applications.
J Clin Epidimiol 1997; 50: 105–16.
37. Strelec MA, Mion AM. The influence of patient’s consciousness regarding high blood pressure and patient’s attitude in face of disease controlling medicine intake. Arc Bras Cardiol 2003; 81: 349–54.
38. Stilley CS, Sereika S, Muldoon MF, Ryan CM, Dunbar-Jacob J. Psychological and cognitive function: predictors of adherence with cholesterol lowering treatment. Ann Behav Med 2004; 27: 117–24.
39. Stewart MA. Effective physician-patient communication and health outcomes: a review. CMAJ 1995; 152 (9): 1423–33.
40. Urquhart J. Role of patient compliance in clinical pharmacokinetics. A review of recent research. Clin Pharmacokinet 1994; 27: 202–15.
41. Waeber B. Treatment strategy to control blood pressure optimally in hypertensive patients. Blood pressure 2001; 10: 62–73.
Авторы
О.С.Левин, А.И.Тумгоева
ГБОУ ДПО Российская медицинская академия последипломного образования, Москва;
Центр экстрапирамидных заболеваний нервной системы ФМБА России
ГБОУ ДПО Российская медицинская академия последипломного образования, Москва;
Центр экстрапирамидных заболеваний нервной системы ФМБА России
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.